Phase II/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis

Using a seamless, adaptive, phase II/III design, the investigators will determine the safety
and efficacy of arimoclomol in patients with SOD1 positive familial ALS. Both stage-1 and
stage-2 are randomized, double-blind and placebo-controlled in a population of patients with
rapidly progressive SOD1 positive familial ALS. Patients with ALS, a history of a relative
affected with ALS (i.e. familial ALS) and the presence of a demonstrable mutation in the SOD1
gene that is known to be associated with rapidly progressive disease, will be eligible for
inclusion in this study. Potentially eligible subjects will undergo screening via telephone
and, if necessary, review of outside medical records. The intervention will continue for up
to 12 months. In the event that a participant reaches a study endpoint (e.g. tracheostomy or
permanently assisted ventilation) study drug will be terminated. Subjects who meet all
eligibility criteria will travel a study site for final eligibility determination, baseline
evaluation and will then be randomized 1:1 to receive either placebo or arimoclomol at a dose
of 200 mg t.i.d. Participants will then be evaluated again in person at a study site at
Month-2. Telephonic evaluations at Month-1, 3, 4, 5, 6, 8, and 10 will be performed in
participants' homes. Safety and tolerability evaluations will be performed at each of these
visits. Collection of blood samples for safety laboratory analyses and measurement of blood
pressure, heart rate, respiratory rate, temperature and weight will be performed at Months-1,
3, 4, 5, 6, 8, and 10 in the participant's home by a representative of a medical monitoring
company. A study coordinator may perform an in-person visit at Month-12, or this visit may
occur telephonically. A final evaluation will be performed via telephone at Month-13 (30 days
after the last dose of study medication).

Inclusion Criteria:

- Type of ALS that is hereditary (runs in families) only.

- El Escorial criteria for familial ALS and a family history of a pathogenic mutation in
a gene known to be associated with ALS, such as the SOD1 gene.

- Willingness to undergo genetic testing and to learn the results.

- Demonstrable mutation in the SOD1 gene that is reported to be associated with a rapid
rate of disease progression (i.e. A4V, A4T, C6F, C6G, V7E, L8Q, G10V, G41S, H43R,
H48Q, D90V, G93A, D101H, D101Y, L106V, I112M, I112T, R115G, L126X, G127X, A145T,
V148G, V148I) or possibly associated with rapidly progressive disease (E21G, G37R,
L38V, D76Y, L84F, L84V, N86S, D90A het, G93R, I104F, I113T, L144F, L144S).

- Age 18 years or older; male or female.

- Capable of providing informed consent and complying with trial procedures.

- Diagnosis within less than 9 months of the anticipated date of the baseline visit AND
study participants' subjective evaluation that they expect their physical condition to
permit travel to the study site for both the baseline and 2-month study visits.

- Women must not be able to become pregnant (e.g. post menopausal for at least one year,
surgically sterile, or practicing adequate birth control methods) for the duration of
the study. Adequate contraception includes: oral contraception, implanted
contraception, intrauterine device in place for at least 3 months, or barrier method
in conjunction with spermicide.

- Women of childbearing potential must have a negative pregnancy test at screening visit
and be non-lactating.

- Willing to remain on a stable dose of Riluzole or to remain off Riluzole for the
duration of the trial.

- Identifiable local medical doctor to assist with urgent care of any medical
complications that may arise.

- Absence of any of the exclusion criteria.

Exclusion Criteria:

- History of known sensitivity or intolerability to Arimoclomol or to any other related
compound.

- Exposure to any investigational drug within 30 days of the screening visit.

- Presence of any of the following clinical conditions:

- Substance abuse within the past year.

- Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active
infectious disease.

- AIDS or AIDS-related complex.

- Unstable psychiatric illness defined as psychosis (hallucinations or delusions),
untreated major depression within 90 days of the screening visit.

- Positive pregnancy test at screening visit.

- Screening laboratory values:

- Creatinine greater than 1.5.

- Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST). greater than
3.0 times the upper limit of normal.

- Total bilirubin greater than 2.0 times the upper limit of normal.

- White blood cell (WBC) count less than 3,500/mm3.

- Platelet concentration less than 100,000/ul.

- Hematocrit level less than 33 for female or less than 35 for male.

- Female patients who are breast-feeding.